Related Experiment Video
Updated: Mar 29, 2026
Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
Published on: June 5, 2010
Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
Patrick Cherin1, Jean-Christophe Delain2, Christophe de Jaeger3
1Department of Internal Medicine, Pitié-Salpetrière Hospital Group, Paris, France.
Introduction:
Inclusion body myositis (IBM) is a slowly progressive degenerative inflammatory disorder affecting both proximal and distal muscles. Immunosuppressive therapies are generally ineffective in the treatment of this disorder, and most patients are resistant to steroid therapy. Some benefits with mild improvement were observed with intravenous immunoglobulin (IVIg), particularly in patients with severe dysphagia.
Objectives:
The objective of this review was to describe the use of subcutaneous Ig (SCIg) in patients with IBM and to assess its feasibility.
Results:
This report reviews 6 cases of IBM treated with SCIg in clinical practice. All patients had received prior treatments for IBM, including immunosuppressive agents and IVIg. SCIg was administered over a long period of time, ranging from 4.5 to 27 months. No patient discontinued the SCIg because of a treatment-related event or safety issues. The 6 cases showed an improvement in muscle strength and resolution of dysphagia. For 2 patients, this improvement persisted for approximately 12 months.
Conclusions:
SCIg might be proposed as an alternative therapy to patients with IBM who are resistant to corticoids and immunosuppressive therapies. Our findings suggest that treatment with SCIg (Gammanorm 16.5%, Octapharma AB) is feasible and safe in patients with IBM.
